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The methodological rigor and high
standard of clinical trials give physi-
cians the confidence that the therapy
prescribed is well-tolerated, demon-
strates clinical efficacy, and (within the
restrictions set by the trial) is appro-
priate for the patient who presents to
the clinic. Given that hidradenitis sup-
purativa (HS) has only one Food and
Drug Administrationeapproved mAb to
date (adalimumab), the plethora of
ongoing clinical trials (van Straalen
et al., 2018) provides solace that mul-
tiple equally (or hopefully more) effi-
cacious therapeutic options will be
available in the future. One of these
new treatment options is bermekimab,
a fully human antibody targeting IL-1a.
Therefore, we read the phase 2 open-
label study of bermekimab in HS by
Gottlieb et al. (2020) with great ex-
pectations. However, we have identi-
fied methodological concerns, which
give a reason for pause and reflection.
The targeted aims of phase 2 studies
often focus on addressing specific
questions before the initiation of a
complex, large, and expensive phase 3
clinical trial. The initial proof-of-
concept study by Kanni et al. (2018)
demonstrated intravenous dosing of
bermekimab as well-tolerated with sig-
nificant changes in disease activity
(60% of patients achieving HS clinical
response [HiSCR]) compared with pla-
cebo (10%). The phase 2 study by
Gottlieb et al. (2020) aimed to assess
tolerability and clinical efficacy of a
subcutaneous dose of bermekimab
(400 mg weekly) with the number of
patients achieving HiSCR at week 12
being the primary outcome of interest.Abbreviations: HiSCR, HS clinical response; HS, hid
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Although the HiSCR is considered the
gold standard outcome measure for HS,
there is considerable discussion
regarding the use of alternative mea-
sures because of issues with elevated
placebo response rates, high interrater
variability, and a lack of assessment of
draining tunnels, which are a highly
burdensome feature of HS (Frew et al.,
2019). The historic initiative has
defined a globally accepted core
outcome set, which is recommended to
be employed in the setting of HS clin-
ical trials (Thorlacius et al., 2018) to aid
comparison between different thera-
pies. This includes data regarding Hur-
ley staging, draining tunnels, and
comorbidities as well as the presenta-
tion of demographic data to assess the
external validity of trial participants
(Thorlacius et al., 2018). Unfortunately,
such data were not presented for this
study (Gottlieb et al., 2020). The
importance of capturing these data in
early-stage proof-of-concept trials is
manifest in light of the recent experi-
ence with IFX-1. IFX-1 is a complement
(C5a) mAb, which demonstrated com-
parable clinical efficacy to adalimumab
in the SHINE phase 2b study
(NCT03487276) (InflaRx, 2019) and
met all secondary end points (including
a significant reduction in pain and
draining tunnels) but did not meet sta-
tistical significance compared with
placebo. This was highly unexpected
because of the high-response rate in an
uncontrolled trial (NCT03001622)
(Giamarellos-Bourboulis et al., 2020).
Although the HiSCR itself as an
outcome measure may haveradenitis suppurativa; LOCF, last observation
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response rates (47%) (Frew et al.,
2019), the fact that the data
regarding efficacy against draining
tunnels were captured (and were
shown to be significant against pla-
cebo) (InflaRx, 2019) highlights the
importance of capturing all relevant
clinical variables in proof-of-concept
clinical trials, especially in uncon-
trolled trials. The emerging evidence
that specific lesions such as draining
tunnels can be associated with treat-
ment response emphasizes the need
for breadth and consistency in core
outcomes in HS clinical trials.
Variations in administered doses of
bermekimab
A major concern regarding methodol-
ogy in this study (Gottlieb et al., 2020)
was the unspecified number of patients
who started the trial with a 200 mg
subcutaneous dose of bermekimab
weekly (as outlined in the methods) but
were increased to a 400 mg subcu-
taneous weekly dose at an unspecified
time point, that is, at the patient’s next
scheduled visit. This deviation from the
original protocol (or protocol implied
in the manuscript) raises significant
concern that this paper presents results
of a cohort of not only patients admin-
istered different doses of bermekimab
(200 mg weekly vs. 400 mg weekly) but
also participants who have received
different doses for different lengths of
time before assessment of the primary
outcome. The lack of consideration of
this ad-hoc dose alteration either
through exclusion or statistical methods
brings into question the validity of the
study results.
Imputation methods for participant
dropout before primary end point
Gottlieb et al. (2020) describe the use
of last observation carried forward
(LOCF) as their imputation method for
participants who withdrew from thewww.jidonline.org 1
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2study or were lost to follow-up (n ¼ 9).
LOCF has been used in a number of
HS-related studies (Casseres et al.,
2020; Zouboulis et al., 2019) as an
imputation method. However, its use is
not recommended in circumstances
where dropout can occur owing to a
lack of efficacy because this leads to an
increased risk of positively biasing
treatment response rates. Verifying the
findings of the LOCF analysis with a
nonresponder imputation, regarding all
withdrawals as secondary to lack of
treatment efficacy, would increase the
validity of the data (National Research
Council, 2010). Given the moderate
rates of achieving clinical outcomes in
HS studies (50e60%), the suitability of
LOCF analysis in HS studies requires
serious consideration. The flaws of
LOCF analysis in HS are clearly illus-
trated by the open-label study of secu-
kinumab in HS (Casseres et al., 2020),
where 13 of 20 patients (65%) ach-
ieved HiSCR at week 12. Using
nonresponder imputation, the number
of participants achieving HiSCR is
revised down to 11 of 20 (55%).
Regarding the data presented by
Gottlieb et al. (2020), when conserva-
tively only applying nonresponder
imputation to those participants who
were lost to follow-up (n ¼ 3, all in
group B) or elected to discontinue
without an alternate reason (n ¼ 2, one
in group A and one in group B), the
revised rates of achieving HiSCR would
equate to 54.2% (n ¼ 13) in group A
and 38.9% (n ¼ 7) in group B. In order
to refute this nonresponder imputation,
an explanation as to the HiSCR status
of participants upon withdrawal would
be required and would be a highly
useful addition to the results of all
future HS clinical trials.Journal of Investigative Dermatology (2020), VolumIn conclusion, high-quality method-
ologies in proof-of-concept uncon-
trolled clinical trials are vital to
accurately assess clinical efficacy. The
results of this phase 2 trial with ber-
mekimab need to be interpreted with
care because they are subject to several
methodological issues. Pause and
consideration of the issues discussed
should be taken before the develop-
ment of phase 3 clinical trials for ber-
mekimab in HS.
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